Aripiprazle in ADHD and ODD
Phase 3
- Conditions
- Attention deficit/hyperactivity disorder.Attention deficit/hyperactivity disorder
- Registration Number
- IRCT20160530028182N6
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Age between 8-18 years
Diagnosis of ADHD and ODD based on DSM5 without effective medication
Taking on mental status at least 2 weeks before the study
Exclusion Criteria
Intelectual disability based on clinical suspicious
Presence of uncontroled siezure
Drug side effects and hypersensivity
Recieving of any other drugs
History of psychological disorder except for ADHD and ODD
Presence of medical diseases such as cardiac diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvment in Attention-deficit symptoms. Timepoint: Baselin, second, fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.
- Secondary Outcome Measures
Name Time Method Severity of ADHD symptoms. Timepoint: Baselin, second, fourth and eighth weeks after intervention. Method of measurement: ADHD Rating scale and CGI.